Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis
Journal
Cells
Journal Volume
10
Journal Issue
12
Pages
3402
Date Issued
2021-12
Abstract
Systemic sclerosis (SSc) is a chronic connective tissue disorder characterized by immune dysregulation, chronic inflammation, vascular endothelial cell dysfunction, and progressive tissue fibrosis of the skin and internal organs. Moreover, increased cancer incidence and accelerated aging are also found. The increased cancer incidence is believed to be a result of chromosome instability. Accelerated cellular senescence has been confirmed by the shortening of telomere length due to increased DNA breakage, abnormal DNA repair response, and telomerase deficiency mediated by enhanced oxidative/nitrative stresses. The immune dysfunctions of SSc patients are manifested by excessive production of proinflammatory cytokines IL-1, IL-6, IL-17, IFN-α, and TNF-α, which can elicit potent tissue inflammation followed by tissue fibrosis. Furthermore, a number of autoantibodies including anti-topoisomerase 1 (anti-TOPO-1), anti-centromere (ACA or anti-CENP-B), anti-RNA polymerase enzyme (anti-RNAP III), anti-ribonuclear proteins (anti-U1, U2, and U11/U12 RNP), anti-nucleolar antigens (anti-Th/T0, anti-NOR90, anti-Ku, anti-RuvBL1/2, and anti-PM/Scl), and anti-telomere-associated proteins were also found. Based on these data, inflamm-aging caused by immune dysfunction-mediated inflammation exists in patients with SSc. Hence, increased cellular senescence is elicited by the interactions among excessive oxidative stress, pro-inflammatory cytokines, and autoantibodies. In the present review, we will discuss in detail the molecular basis of chromosome instability, increased oxidative stress, and functional adaptation by deranged immunome, which are related to inflamm-aging in patients with SSc.
Subjects
anti-centromere antibody; anti-topoisomerase 1 antibody; cellular senescence; chromosome instability; immune functional adaptation; inflamm-aging; oxidative stress; proinflammatory cytokines; systemic sclerosis; tissue fibrosis
Anti-centromere antibody; Anti-topoisomerase 1 antibody; Cellular senescence; Chromosome instability; Immune functional adaptation; Inflamm-aging; Oxidative stress; Proinflammatory cytokines; Systemic sclerosis; Tissue fibrosis
SDGs
Other Subjects
alpha interferon; autoantibody; CXCL13 chemokine; CXCL9 chemokine; DNA directed RNA polymerase III; DNA methyltransferase; DNA topoisomerase; fibroblast growth factor receptor 2; high mobility group B1 protein; histone acetyltransferase; histone deacetylase; HLA DQ antigen; HLA DQ5 antigen; interleukin 1; interleukin 17; interleukin 2 receptor alpha; interleukin 21; interleukin 23 receptor; interleukin 6; Ku antigen; non receptor protein tyrosine phosphatase 22; OX40 ligand; ribonucleoprotein; RNA polymerase; STAT3 protein; STAT4 protein; telomerase; toll like receptor; toll like receptor 2; transcription factor DLX5; transcription factor FOXP3; transcription factor T bet; tumor necrosis factor; unclassified drug; autacoid; autoantibody; adaptive immunity; aging; antigen presenting cell; antiinflammatory activity; bioinformatics; CD4+ T lymphocyte; CD8+ T lymphocyte; cell differentiation; centromere; chromosomal instability; chronic inflammation; cytokine production; DNA damage response; DNA repair; DNA strand breakage; environmental factor; enzyme deficiency; epigenetics; gene expression; genetic predisposition; histone modification; human; immune dysregulation; immune response; immunological tolerance; inflammaging; inflammation; major histocompatibility complex; multiple sclerosis; nitrative stress; oxidative stress; regulatory T lymphocyte; Review; rheumatoid arthritis; single nucleotide polymorphism; synaptic transmission; systemic lupus erythematosus; systemic sclerosis; telomere length; tumor associated leukocyte; vascular endothelial cell; aging; complication; endothelium cell; fibrosis; genetics; immunology; immunopathology; pathology; skin disease; systemic sclerosis; Aging; Autoantibodies; Endothelial Cells; Fibrosis; Humans; Immune System Diseases; Inflammation; Inflammation Mediators; Scleroderma, Systemic; Skin Diseases
Publisher
MDPI
Type
journal article